Molecular pathology and clinical implications of diffuse glioma

作     者：Ruichao Chai Shengyu Fang Bo Pang Yuqing Liu Yongzhi Wang Wei Zhang Tao Jiang Ruichao Chai;Shengyu Fang;Bo Pang;Yuqing Liu;Yongzhi Wang;Wei Zhang;Tao Jiang

作者机构：Department of Molecular NeuropathologyBeijing Neurosurgical InstituteCapital Medical UniversityBeijing 100070China Department of NeurosurgeryBeijing Tiantan HospitalCapital Medical UniversityBeijing 100070China Research Unit of Accurate DiagnosisTreatmentand Translational Medicine of Brain TumorsChinese Academy of Medical SciencesBeijing 100070China 

出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)

年 卷 期：2022年第135卷第24期

页      面：2914-2925页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Beijing Nova Program(No.Z201100006820118) National Natural Science Foundation of China(Nos.82192894 and 81903078) Research Unit of Accurate Diagnosis,Treatment,and Translational Medicine of Brain Tumors Chinese(No.2019-I2M-5-021) 

主　　题：Glioma Molecular pathology tumor classification O^(6)-methylguanine-DNA methyltransferase Therapy 

摘      要：The prognosis for diffusely infiltrating gliomas at World Health Organization(WHO)grade 2-4 remains dismal due to their heterogeneity.The rapid development of genome-wide molecular-profiling-associated studies has greatly promoted the accuracy of glioma classification.Thus,the latest version of the WHO classification of the central nervous system tumors published in 2021 has incorporated more molecular biomarkers together with histological features for the diagnosis of gliomas.Advanced usage of molecular pathology in clinical diagnostic practice provides also new opportunities for the therapy of patients with glioma,including surgery,radiotherapy and chemotherapy,targeted therapy,immunotherapy,and more precision clinical trials.Herein,we highlight the updates in the classification of gliomas according to the latest WHO guidelines and summarize the clinically relevant molecular markers by focusing on their applications in clinical practice.We also review the advances in molecular features of gliomas,which can facilitate the development of glioma therapies,thereby discussing the challenges and future directions of molecular pathology toward precision medicine for patients with glioma.